Drug Profile
TAS 0728
Alternative Names: TAS0728; TPC 107Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 27 Mar 2021 Taiho Oncology completes a phase-I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in France (PO) (EudraCT2017-004415-39)
- 27 Mar 2021 Taiho Oncology terminates a phase-I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain (PO) due to unacceptable toxicity during the dose-escalation (NCT03410927)
- 15 Mar 2021 Phase I/II trial is still ongoing for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain, France, United Kingdom, USA (PO) (NCT03410927)